Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) is set to present at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 1:30 PM ET. CEO Jeffrey Stein will provide a corporate overview highlighting the company’s commitment to developing long-acting therapeutics for severe fungal and viral infections. Cidara's lead candidate is rezafungin, part of its innovative Cloudbreak® antiviral platform. Investors can access the live audio webcast on the company’s website.

News Market Reaction – CDTX

-4.96%

-4.96% Session move

In the trading session that priced this news, CDTX declined 4.96%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 20^th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021.

Presentation Information:
Date:	Wednesday, April 14, 2021
Time:	1:30 PM ET
Webcast:	A live audio webcast and replay of the presentation will be available in the Investors section on the company’s website at www.cidara.com.

About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com

FAQ

What will Cidara Therapeutics present at the Needham Virtual Healthcare Conference on April 14, 2021?

Cidara Therapeutics will present a corporate overview led by CEO Jeffrey Stein at 1:30 PM ET.

What is the focus of Cidara Therapeutics' development efforts?

Cidara Therapeutics is focused on long-acting therapeutics for serious fungal and viral infections.

Where can I watch Cidara's presentation from the conference?

The presentation will be available via live audio webcast on Cidara's website.

What is Cidara Therapeutics' lead antifungal candidate?

Cidara's lead antifungal candidate is rezafungin.

What is the Cloudbreak® platform mentioned in the Cidara PR?

The Cloudbreak® platform is Cidara’s proprietary technology for developing antiviral conjugates.